Daejeon, South Korea

Se Jin Jung


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Se Jin Jung: Innovator in Metabolic Disease Treatment

Introduction

Se Jin Jung is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of metabolic disease treatment through his innovative research and development. With a total of 2 patents to his name, Jung is recognized for his dedication to advancing medical science.

Latest Patents

Jung's latest patents include a composition comprising a CYP4A-inhibiting compound as an active ingredient for preventing or treating metabolic diseases. This invention specifically relates to a composition that includes the compound expressed by chemical formula 1 or its pharmaceutically acceptable salt. The aim is to prevent, ameliorate, or treat metabolic diseases effectively. Another notable patent involves an ionic compound, along with a coating composition and an organic light-emitting device that incorporates this compound. These inventions showcase his commitment to addressing critical health issues through innovative solutions.

Career Highlights

Throughout his career, Se Jin Jung has worked with reputable organizations such as LG Chem, Ltd and the Korea Basic Science Institute. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Ho Gyu Lee and Seog Jae Seo. Their collaborative efforts have further enhanced the impact of Jung's inventions in the scientific community.

Conclusion

Se Jin Jung stands out as a dedicated inventor whose work in metabolic disease treatment is paving the way for future advancements in healthcare. His innovative patents and collaborations reflect his commitment to improving human health through science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…